Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31119408 | 1.00 | COMT (0.70) | COMTMAPTERN1TTRRAB9A | |
| SCHEMBL3586761 | 0.93 | COMT (0.63) | COMTMAPTERN1TTRRAB9A | |
| SCHEMBL3590986 | 0.93 | COMT (0.66) | COMTMAPTERN1TTRRAB9A | |
| SCHEMBL3586288 | 0.91 | COMT (0.69) | COMTMAPTERN1TTRRAB9A | |
| SCHEMBL8471833 | 0.88 | COMT (0.55) | COMTMAPTRAB9ANPC1HPGD | |
| SCHEMBL3591312 | 0.88 | COMT (0.55) | COMTMAPTRAB9ANPC1HPGD | |
| SCHEMBL30471666 | 0.88 | COMT (0.55) | COMTMAPTRAB9ANPC1HPGD | |
| SCHEMBL3594892 | 0.87 | COMT (0.64) | COMTMAPTERN1TTRRAB9A | |
| SCHEMBL3582092 | 0.85 | COMT (0.55) | COMTMAPTERN1TTRRAB9A | |
| SCHEMBL3592910 | 0.85 | COMT (0.54) | COMTMAPTERN1TTRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2413913-B1 | PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THE SAME | BIAL PORTELA & CA SA (PT) | 2022-05-18 | — | — | EP | claimed |
| US-20210315824-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THE SAME | BIAL - PORTELA & CA, S.A. (PT) | 2021-10-14 | — | — | US | claimed |
| US-10583130-B2 | Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof | BIAL-PORTELA & CA, S.A. (PT) | 2020-03-10 | — | — | US | claimed |
| EP-2413912-B1 | PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THEREOF | BIAL PORTELA & CA SA (PT) | 2019-03-13 | — | — | EP | claimed |
| US-20190008774-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THE SAME | BIAL - PORTELA & Cª, S.A. (PT) | 2019-01-10 | — | — | US | claimed |
| EP-3421456-A1 | NEW ROUTE OF SYNTHESIS FOR OPICAPONE | AZAD Pharmaceutical Ingredients AG (CH) | 2019-01-02 | — | — | EP | claimed |
| US-20180370958-A1 | Route Of Synthesis For Opicapone | AZAD PHARMACEUTICAL INGREDIENTS AG (CH) | 2018-12-27 | — | — | US | claimed |
| US-20180333402-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THEREOF | BIAL - PORTELA & CA, S.A. (PT) | 2018-11-22 | — | — | US | claimed |
| US-10071085-B2 | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof | BIAL—PORTELA & CA, S.A. (PT) | 2018-09-11 | — | — | US | claimed |
| US-9446012-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-09-20 | — | — | US | claimed |
| EP-2259777-A2 | PHARMACEUTICAL COMPOSITION FOR POORLY SOLUBLE DRUGS | BIAL - Portela & Ca., S.A. (PT) | 2010-12-15 | — | — | EP | claimed |
| WO-2010114404-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THEREOF | BIAL - PORTELA & CA., S.A. (PT) | 2010-10-07 | — | — | WO | claimed |
| WO-2010114405-A2 | PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THE SAME | BIAL - PORTELA & CA., S.A. (PT) | 2010-10-07 | — | — | WO | claimed |
| US-20100256194-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THE SAME | BIAL - PORTELA & CA, S.A. (PT) | 2010-10-07 | — | — | US | claimed |
| US-20100256193-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THEREOF | BIAL - PORTELA & CA, S.A. (PT) | 2010-10-07 | — | — | US | claimed |
| US-20100168113-A1 | Pharmaceutical Compounds | BIAL-PORTELA & CA., S.A. (PT) | 2010-07-01 | — | — | US | claimed |
| WO-2009108077-A2 | PHARMACEUTICAL COMPOSITION FOR POORLY SOLUBLE DRUGS | BIAL - PORTELA & CA., S.A. (PT) | 2009-09-03 | — | — | WO | claimed |
| EP-2027091-A1 | NEW PHARMACEUTICAL COMPOUNDS | BIAL - Portela & Ca., S.A. (PT) | 2009-02-25 | — | — | EP | claimed |
| WO-2007117165-A1 | NEW PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2007-10-18 | — | — | WO | claimed |
| EP-1845097-A1 | Oxadiazole derivatives as COMT inhibitors | Portela & Ca., S.A. (PT) | 2007-10-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190008774-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THE SAME | NNT, NQO1, ABCG2 | COMT 10/4885MAPT 1017/4885ERN1 3942/4885 |
| US-20100168113-A1 | Pharmaceutical Compounds | PMP22, CNR2, OPRL1 | COMT 10/4885MAPT 310/4885ERN1 4399/4885 |
| US-20100256194-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THE SAME | NNT, NQO1, ABCG2 | COMT 10/4885MAPT 1017/4885ERN1 3942/4885 |
| US-20210315824-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THE SAME | NNT, NQO1, ABCG2 | COMT 10/4885MAPT 1017/4885ERN1 3942/4885 |
| US-20100256193-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THEREOF | NNT, NQO1, ABCG2 | COMT 5/4885MAPT 928/4885ERN1 3804/4885 |
| US-20180370958-A1 | Route Of Synthesis For Opicapone | OPRM1, OPRK1, OPRD1 | COMT 399/4885MAPT 4473/4885ERN1 1818/4885 |
| US-10583130-B2 | Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof | NNT, NQO1, CYP2D6 | COMT 10/4885MAPT 951/4885ERN1 3776/4885 |
| US-10071085-B2 | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof | NNT, NQO1, ABCG2 | COMT 5/4885MAPT 928/4885ERN1 3804/4885 |
| US-20180333402-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THEREOF | NNT, NQO1, ABCG2 | COMT 5/4885MAPT 928/4885ERN1 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.